Medibact GuidesShop at Medibact

Stacking Module

Sermorelin Stacking Module

Sermorelin is the GHRH analog with the strongest regulatory history in this group — it was an approved product for growth-hormone deficiency diagnosis — which is why it appears more often in supervised settings than the research-market GHRH analogs. Its stacking logic is standard for the class; its short half-life is what distinguishes it in practice.

Sermorelin Guide at MedibactSermorelin calculatorPeptide Stacking Guide

Educational use only — not medical advice. This page summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.

How to think about stacking Sermorelin

  • Sermorelin is GHRH(1-29), the closest of these compounds to native GHRH. Its partner is a ghrelin-receptor secretagogue, not another GHRH analog.
  • Its half-life is very short, so reported protocols emphasise timing — typically bedtime, fasted — more than for long-acting analogs.
  • Because it acts upstream on a pulsatile axis, it is described as preserving the body's own feedback regulation, unlike administering GH directly. That framing is the usual rationale for the whole class.
  • No controlled trial has studied Sermorelin combined with anything.

Combinations in detail

Sermorelin + Ipamorelin

GHRH analog + selective secretagogue
Why it is proposed
The standard two-pathway pairing with the most conservatively-framed components: Sermorelin is closest to native GHRH and Ipamorelin is the selective secretagogue reported not to drive cortisol or prolactin.
What is reported in practice
Reported as a bedtime subcutaneous pairing, fasted, drawn together.
Cautions specific to this combination
Sermorelin's short duration makes timing errors more consequential than with CJC-1295 DAC. Nothing about the pairing has been studied as a combination.

Sermorelin + GHRP-2

GHRH analog + older secretagogue
Why it is proposed
Same construction with a more potent older secretagogue on the GH-release side.
What is reported in practice
Reported as a stronger-pulse alternative to the Ipamorelin pairing.
Cautions specific to this combination
GHRP-2 is reported to affect cortisol and prolactin more than Ipamorelin — the trade-off is potency against selectivity.

Sermorelin + BPC-157 + TB-500

GH-axis support + repair pairing
Why it is proposed
Systemic GH-axis support alongside local tissue repair; distinct mechanisms with no overlap.
What is reported in practice
Separate vials, separate schedules.
Cautions specific to this combination
Scale differences across three compounds; recompute each. No combination data exists.

What to avoid, and why

  • Pairing two GHRH analogs (Sermorelin, CJC-1295, Mod GRF 1-29, Tesamorelin) is described as redundant rather than additive — they act at the same receptor. Mod GRF 1-29 is CJC-1295 without the DAC modification, so combining those two is close to running one compound against itself.
  • Adding Tesamorelin or CJC-1295 to Sermorelin — all three are GHRH analogs.
  • Treating Sermorelin's approved-drug history as evidence for any stack containing it; that history covers diagnostic use of the single compound.

Related reading

The Peptide Stacking GuideAll stacking pages

Every combination described here is reported practice or mechanism-level reasoning. No controlled trial has studied any of these combinations, and nothing on this page is a personal protocol, a dose recommendation, or medical advice.